Table 1. Clinic-pathologic variables and immune-activity status of PD-1 and PD-L1 in 132 patients with recurrent NPC.
| Variables | n | PD-1positive | P value1 | PD-L1High | P value1 | |
|---|---|---|---|---|---|---|
| Gender | Male | 106 | 41 (38.7%) | 0.702 | 68 (64.2%) | 0.216 |
| Female | 26 | 9 (34.6%) | 20 (76.9%) | |||
| Age at recurrence (years) | ≤ 50 | 87 | 32 (36.8%) | 0.718 | 58 (66.7 %) | 1.000 |
| > 50 | 45 | 18 (40.0%) | 30 (66.7%) | |||
| Time to recurrence (months) | ≤ 24 | 44 | 13 (29.5%) | 0.163 | 26 (59.1%) | 0.192 |
| > 24 | 88 | 37 (42.0%) | 62 (70.5%) | |||
| Smoking status | Smoker or ex-smoker | 52 | 22 (42.3%) | 0.398 | 34 (65.4%) | 0.801 |
| Non-smoker | 80 | 28 (35.0%) | 54 (67.5%) | |||
| Family history | Yes | 28 | 13 (46.4%) | 0.293 | 17 (60.7%) | 0.452 |
| No | 104 | 37 (35.6%) | 71 (68.3%) | |||
| Histotype classification (WHO) | II | 7 | 1 (14.3%) | 0.186 | 5 (71.4%) | 0.784 |
| III | 125 | 49 (39.2%) | 83 (66.4%) | |||
| r-T classification | rT1-2 | 31 | 14 (45.2%) | 0.339 | 13 (41.9%) | 0.001** |
| rT3-4 | 101 | 36 (35.6%) | 75 (74.3%) | |||
| r-N category | N0 | 100 | 37 (37.0%) | 0.713 | 66 (66.0%) | 0.774 |
| N1-3 | 32 | 13 (40.6%) | 22 (68.8%) | |||
| Clinical stage of recurrent tumour2 | I-II | 31 | 14 (45.2%) | 0.339 | 13 (41.9%) | 0.001** |
| III-IV | 101 | 36 (35.6%) | 75 (74.3%) | |||
| Tumor necrosis before retreatment | Yes | 49 | 18 (36.7%) | 0.835 | 34 (69.4%) | 0.610 |
| No | 83 | 32 (38.6%) | 54 (65.1%) | |||
| HB levels at local recurrence | Anemia3 | 32 | 11 (34.4%) | 0.639 | 26 (81.3%) | 0.044* |
| No anemia | 100 | 39 (39.0%) | 62 (62.0%) | |||
| Salvage treatments | RT4 only | 43 | 20 (46.5%) | 0.651 | 27 (62.8%) | 0.111 |
| RT4with CT5 | 80 | 31 (38.8%) | 58 (72.5%) | |||
| Surgery6 | 6 | 2 (33.3%) | 2 (33.3%) | |||
| Radiofrequency ablation6 | 3 | 2 (66.7%) | 1 (33.3%) | |||
| Cause of deaths | Disease progression | 45 | 19 (42.2%) | 0.794 | 36 (80.0%) | 0.024* |
| Other disease | 2 | 1 (50.0%) | 1 (50.0%) | |||
| Severe adverse effects | 35 | 12 (34.3%) | 26 (74.3%) | |||
| Unknown | 5 | 3 (60.0%) | 3 (60.0%) |
1According to the 7th Edition of the AJCC / UICC Staging System for Nasopharyngeal Cancer. 2Anemia was defined according to World Health Organization criteria as hemoglobin <130 g/l in men and <120 g/l in women. 3Radiotherapy (RT) were proscribed to 114 patients by IMRT, 6 patients with conventional radiotherapy, 2 with stereotactic radiotherapy and 1 with brachytherapy. 4Combined chemotherapy (CT) were administered to 80 patients with RT. 5Induction chemotherapy were used in 2 out of 6 patients who received salvage surgery and 1 out of 3 patients treated with radiofrequency ablation.